Roche and Wellthy Therapeutics partnered last year to test self-management practices for Type 2 diabetes using Roche's Accu-Chek and Wellthy's digital therapeutic (DTx). The study found that those with the highest engagement with Wellthy's DTx saw the largest reduction in blood sugar levels. The results were especially encouraging because they were found in a real-world setting, as opposed to a clinical trial setting. Roche has moved quickly to build a digital diabetes management ecosystem in a resource-constrained and low-health-literacy market. This is a great example of a foreign multinational tailoring its approach to fit local market needs and partnering with a local startup that's well-placed to understand local consumer behavior.
For the original news article,